Movano (MOVE) Appoints Medtech Industry Veteran John Mastrototaro, PhD, as CEO
- U.S. stocks close down on news of Biden tax proposal
- Biden To Propose Capital Gains Tax As High As 43.4% For Wealthy - Bloomberg
- Intel (INTC) Tops Q1 EPS by 24c, Offers Guidance
- Snap (SNAP) Tops Q1 EPS by 5c, DAUs were 280 million, Offers Guidance
- Credit Suisse (CS) Falls 6% on 'Unacceptable Loss' as Exposure to Archegos Grew to More Than $20 Billion, Set to Raise Over $2 Billion to Support Liquidity
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
As the pioneer of the first FDA-approved continuous glucose monitor, Dr. Mastrototaro will be integral in advancing the development and regulatory process of the Company's glucose and blood pressure monitoring technology
Today, Movano Inc. (NASDAQ: MOVE), a health technology company designing devices that empower individuals to optimize their health in order to prevent and better manage chronic diseases, announced current Director, Dr. John Mastrototaro, will join the Company as CEO, effective April 1, 2021. Movano's founder and current CEO, Michael Leabman, will become the Company's CTO and will remain on the Company's Board of Directors. Dr. Mastrototaro's 30+ years of experience in the medical device industry, leading innovation and bringing new products to the market will provide critical medtech expertise, strategic vision and bolster the Company's growth profile.
"As we continue the development of our technology, which will measure glucose, blood pressure and other health data non-invasively and continuously, it is a major vote of confidence to have a key opinion leader in the medtech industry, like John, shaping our vision and driving us forward," said Michael Leabman, founder and CTO of Movano. "John's experience building and growing market-leading medical devices and extensive understanding of how to work with the FDA will help the Company successfully commercialize its products, carving a path to develop a variety of devices that suit specialized medical needs, generate significant consumer appeal and improve health outcomes."
Prior to joining Movano, Dr. Mastrototaro was COO of OrthoSensor, Inc., which was recently acquired by Stryker (NYSE: SYK). Before that, he spent 25 years with MiniMed and Medtronic, where he was instrumental in initiating and leading a series of firsts in the world of diabetes, including the ambulatory continuous glucose monitoring system, the sensor augmented insulin pump and the early generations of the artificial pancreas. During his tenure in Medtronic's Diabetes division, Dr. Mastrototaro held a number of positions, including CTO, VP of R&D and Business Development and Global VP of Clinical Research and Health Affairs. He was also Medtronic's first VP of Informatics, where he helped develop a corporate strategy for the use of data and analytics to improve healthcare delivery.
"I've devoted the majority of my career to improving the lives of people with diabetes through data. The key to improving outcomes for health-conscious individuals, including those with or at risk of diabetes, hypertension and other chronic disease, is increased visibility into glucose and blood pressure metrics," said Dr. Mastrototaro, Movano's incoming CEO. "What attracted me to Movano was the company's unique approach to getting real-time data that matters most into the hands of users, allowing them to take control of their health journey. With immediate and actionable feedback on how diet, activity and stress affects one's health, Movano's proprietary technology will give individuals a simple, smart and personalized tool to help them optimize for good health today and prevent, delay or alleviate the effects of chronic disease in the future."
To learn more about Movano Inc., please visit www.movano.com.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Parker-Hannifin (PH) Reports Election of William F. Lacey to Board
- Quidel Corp (QDEL) Prelim. Q1 Revenue Misses Consensus
- Socket Mobile (SCKT) Reports Q1 EPS of $0.03, Revenues Beat
Create E-mail Alert Related CategoriesCorporate News, Management Changes, Management Comments
Related EntitiesS1, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!